Company: ARAI
Filing Date: 2025-07-15
Form Type: S-1/A
Source: 0001641172-25-019572
Chunk: 143

Company: Arrive AI Inc.
Filing Date: 2025-07-15
Form: S-1/A
Chunk 143
---
 has 60 days to cure. If the default is not cured, the license transitions to a non-exclusive
license, allowing both parties to seek additional licensees or sources for similar technology, while royalty payments continue into perpetuity
or until the 20-year patent term ends. The Second Amendment also removes prior restrictions on the Company’s use, sale, or commercialization
of the technology after termination, permitting the sale of remaining inventory for up to 90 days post-termination, provided all required
reports and payments are made under the Agreement. The foregoing description of the license agreement is not complete and is qualified
in its entirety by reference to the text of such document, which is filed as an exhibit to our Direct Listing Registration Statement.

<div align='center'>PRINCIPAL AND REGISTERED STOCKHOLDERS</div>

Security Ownership of Certain Beneficial Owners and Management

The following table sets forth certain information
regarding the beneficial ownership of our common stock as of July 13, 2025 by (a) each stockholder who is known to us to own beneficially
5% or more of our outstanding common stock; (b) all directors; (c) our executive officers, and (d) all executive officers and directors
as a group. Except as otherwise indicated, all persons listed below have (i) sole voting power and investment power with respect to their
common stock, except to the extent that authority is shared by spouses under applicable law, and (ii) record and beneficial ownership
with respect to their common stock.

The Stockholders include substantially all holders
of our common stock, including (i) affiliates of the Company and certain other stockholders with “restricted securities”
(as defined in Rule 144 under the Securities Act) who, because of their status as affiliates pursuant to Rule 144 or because they acquired
their common stock from an affiliate or the Company within the prior 12 months, would be unable to sell their securities pursuant to
Rule 144 until the Company has been subject to the reporting requirements of Section 13 or Section 15(d) the Exchange Act for a period
of at least 90 days and (ii) our employees. None of such outstanding shares as of the date of this prospectus and registered herein may
be freely sold in reliance on an exemption from registration such as Rule 144 at this time. The Stockholders may, or may not, elect to
sell their common stock through transactions on Nasdaq at prevailing market prices. As such, the Company